Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study

[1]  Jiarui He,et al.  Effects of inactivated SARS‐CoV‐2 vaccination on male fertility: A retrospective cohort study , 2022, Journal of medical virology.

[2]  D. Gkentzi,et al.  Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives , 2022, Vaccines.

[3]  Jiayou Zhang,et al.  The Epidemiology of Influenza and the Associated Vaccines Development in China: A Review , 2022, Vaccines.

[4]  Xiaoming Yang,et al.  Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial , 2022, Human vaccines & immunotherapeutics.

[5]  S. Malaivijitnond,et al.  Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity , 2022, Vaccine.

[6]  J. Ortiz,et al.  Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons , 2022, Vaccines.

[7]  V. Male.  SARS-CoV-2 infection and COVID-19 vaccination in pregnancy , 2022, Nature Reviews Immunology.

[8]  M. R. Caro,et al.  Effect of Female Sex Hormones on the Immune Response against Chlamydia abortus and on Protection Conferred by an Inactivated Experimental Vaccine in a Mouse Model , 2022, Pathogens.

[9]  M. Postma,et al.  A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019-2020 Influenza Season in the United States. , 2021, Open forum infectious diseases.

[10]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[11]  Jiayou Zhang,et al.  AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice , 2021, AAPS PharmSciTech.

[12]  Xiaoming Yang,et al.  Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study , 2021, Human vaccines & immunotherapeutics.

[13]  L. Pomar,et al.  SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland , 2021, Viruses.

[14]  U. Reichl,et al.  High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells , 2021, Applied Microbiology and Biotechnology.

[15]  Irina Isakova-Sivak,et al.  Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model , 2021, Microorganisms.

[16]  Manisha Pandey,et al.  Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines , 2021, Scientific reports.

[17]  K. Pang,et al.  Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics , 2021, Frontiers in Immunology.

[18]  S. Walker,et al.  The historical aspects of vaccination in pregnancy , 2020, Best Practice & Research Clinical Obstetrics & Gynaecology.

[19]  G. Dekker,et al.  Safety and protective effects of maternal influenza vaccination on pregnancy and birth outcomes: A prospective cohort study , 2020, EClinicalMedicine.

[20]  M. Postma,et al.  A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season. , 2020, Vaccine.

[21]  S. de Lusignan,et al.  The impact of candidate influenza virus and egg-based manufacture on vaccine effectiveness: Literature review and expert consensus. , 2020, Vaccine.

[22]  Stephanie A. Jones,et al.  Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial , 2020, The lancet. HIV.

[23]  M. Tashiro,et al.  Comparison of suspension MDCK cells, adherent MDCK cells, and LLC‐MK2 cells for selective isolation of influenza viruses to be used as vaccine seeds , 2019, Influenza and other respiratory viruses.

[24]  T. D. de Silva,et al.  The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review. , 2019, The Lancet. Infectious diseases.

[25]  Chi‐Huey Wong,et al.  Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections , 2019, Proceedings of the National Academy of Sciences.

[26]  J. Noh,et al.  Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults , 2018, Human vaccines & immunotherapeutics.

[27]  L. Joosten,et al.  The impact of sex hormones on BCG‐induced trained immunity , 2018, Journal of leukocyte biology.

[28]  Gavin J. D. Smith,et al.  Influenza , 2018, Nature Reviews Disease Primers.

[29]  N. Akhmatova,et al.  Immunogenicity and safety of subunit influenza vaccines in pregnant women , 2018, ERJ Open Research.

[30]  Seth J. Zost,et al.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains , 2017, Proceedings of the National Academy of Sciences.

[31]  T. Kepler,et al.  Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain , 2016, Nature Medicine.

[32]  Honglin Chen,et al.  Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine , 2016, Oncotarget.

[33]  R. Mills,et al.  Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study , 2016, Human vaccines & immunotherapeutics.

[34]  E. Forleo-Neto,et al.  Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[35]  N. Hegde.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future , 2015, Human vaccines & immunotherapeutics.

[36]  D. Skowronski,et al.  Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses , 2014, PloS one.

[37]  Yan Liu,et al.  Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu® , 2014, Human vaccines & immunotherapeutics.

[38]  J. Manske.  Efficacy and Effectiveness of Maternal Influenza Vaccination During Pregnancy: A Review of the Evidence , 2014, Maternal and Child Health Journal.

[39]  C. Combescure,et al.  Influenza Vaccination Given at Least 2 Weeks Before Delivery to Pregnant Women Facilitates Transmission of Seroprotective Influenza-specific Antibodies to the Newborn , 2013, The Pediatric infectious disease journal.

[40]  S. Omer,et al.  Safety of influenza immunization during pregnancy for the fetus and the neonate. , 2012, American journal of obstetrics and gynecology.

[41]  A. Crucitti,et al.  Manufacturers' postmarketing safety surveillance of influenza vaccine exposure in pregnancy. , 2012, American journal of obstetrics and gynecology.

[42]  G. Tannock,et al.  Cell-Based Influenza Vaccines , 2012, Drugs.

[43]  L. Xing,et al.  MDCK cell-cultured influenza virus vaccine protects mice from lethal challenge with different influenza viruses , 2012, Applied Microbiology and Biotechnology.

[44]  Nandini Shetty,et al.  Emerging, Novel, and Known Influenza Virus Infections in Humans , 2010, Infectious Disease Clinics of North America.

[45]  Sung Whan Cho,et al.  Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination. , 2010, Vaccine.

[46]  J. Lebrón,et al.  Nonclinical safety assessment of vaccines and adjuvants. , 2010, Methods in molecular biology.

[47]  C. Weiner,et al.  Medications in Pregnancy and Lactation: Part 1. Teratology , 2009, Obstetrics and gynecology.

[48]  Kevin M. White,et al.  Anaphylaxis from the Influenza Virus Vaccine , 2007, International Archives of Allergy and Immunology.

[49]  M. Tashiro,et al.  Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host‐cell adaptation , 2004, Journal of medical virology.

[50]  B. Wahrén,et al.  Protection against influenza virus challenge by topical application of influenza DNA vaccine. , 2001, Vaccine.

[51]  N. Cox,et al.  Nonimmunoselected intrastrain genetic variation detected in pairs of high-yielding influenza A (H3N2) vaccine and parental viruses. , 1994, The Journal of infectious diseases.

[52]  R. Couch,et al.  Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes , 1990, Journal of virology.

[53]  R. Webster,et al.  Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. , 1989, The Journal of infectious diseases.